On September 9, 2021 AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, reported that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the H.C. Wainwright 23rd Annual Global Investment Conference (Press release, AnaptysBio, SEP 9, 2021, View Source [SID1234590737]). The presentation will be available on Monday September 13, 2021, at 7:00 a.m. ET via: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will also be available through the investor section of the AnaptysBio website at View Source A replay of the webcast will be available for 90 days following the event.